Binding of sodium channel inhibitors to hyperpolarized and depolarized conformations of the channel

Neuropharmacology

Volumn 60, Issue 1, 2011, Pages 191-200

  Lenkey, N ^a   Karoly, R ^a   Epresi, N ^a   Vizi, E S ^a   Mike, A ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Chemical descriptors; Inactivated state affinity; Local anesthetic; Resting affinity; Sodium channel inhibitor; Structure activity relationship

Indexed keywords

LIDOCAINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.8; SODIUM CHANNEL NAV1.8 INHIBITOR; TETRYLAMMONIUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DEPOLARIZATION; DRUG POTENCY; DRUG PROTEIN BINDING; HYDROGEN BOND; HYPERPOLARIZATION; IC 50; MEMBRANE ELECTROPHYSIOLOGY; MOLECULAR WEIGHT; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; STEADY STATE; STRUCTURE ACTIVITY RELATION; VOLTAGE CLAMP;

ELECTROPHYSIOLOGY; MODELS, THEORETICAL; PROTEIN CONFORMATION; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149500252     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.08.005     Document Type: Article

References (60)

1. Ahern C.A., Eastwood A.L., Dougherty D.A., Horn R. Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ. Res. 2008, 102:86-94.
2. Armstrong C.M. Na channel inactivation from open and closed states. Proc. Natl. Acad. Sci. U S A 2006, 103:17991-17996.
3. Bean B.P., Cohen C.J., Tsien R.W. Lidocaine block of cardiac sodium channels. J. Gen. Physiol. 1983, 81:613-642.
4. Bokesch P.M., Post C., Strichartz G. Structure-activity relationship of lidocaine homologs producing tonic and frequency-dependent impulse blockade in nerve. J. Pharmacol. Exp. Ther. 1986, 237:773-781.
5. Bosmans F., Martin-Eauclaire M.F., Swartz K.J. Deconstructing voltage sensor function and pharmacology in sodium channels. Nature 2008, 456:202-208.
6. Brochu R.M., Dick I.E., Tarpley J.W., McGowan E., Gunner D., Herrington J., Shao P.P., Ok D., Li C., Parsons W.H., Stump G.L., Regan C.P., Lynch J.J., Lyons K.A., McManus O.B., Clark S., Ali Z., Kaczorowski G.J., Martin W.J., Priest B.T. Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol. Pharmacol. 2006, 69:823-832.
7. Brown M.L., Brown G.B., Brouillette W.J. Effects of log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel. J. Med. Chem. 1997, 40:602-607.
8. Brown M.L., Zha C.C., Van Dyke C.C., Brown G.B., Brouillette W.J. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J. Med. Chem. 1999, 42:1537-1545.
9. Carter A.J., Grauert M., Pschorn U., Bechtel W.D., Bartmann-Lindholm C., Qu Y., Scheuer T., Catterall W.A., Weiser T. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL. Proc. Natl. Acad. Sci. U S A 2000, 97:4944-4949.
10. Catterall W.A. Activation of the action potential Na+ ionophore by neurotoxins. An allosteric model. J. Biol. Chem. 1977, 252:8669-8676.
11. Chanda B., Bezanilla F. Tracking voltage-dependent conformational changes in skeletal muscle sodium channel during activation. J. Gen. Physiol. 2002, 120:629-645.
12. Clutterbuck L.A., Posada C.G., Visintin C., Riddall D.R., Lancaster B., Gane P.J., Garthwaite J., Selwood D.L. Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J. Med. Chem. 2009, 52:2694-2707.
13. Courtney K.R., Strichartz G.R. Structural elements which determine local anesthetic activity. Local Anesthetics 1987, 53-89. Springer-Verlag, Berlin. G.R. Strichartz (Ed.).
14. Ehring G.R., Moyer J.W., Hondeghem L.M. Quantitative structure activity studies of antiarrhythmic properties in a series of lidocaine and procainamide derivatives. J. Pharmacol. Exp. Ther. 1988, 244:479-492.
15. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today 2004, 9:276-285.
16. Elliott J.R., Haydon D.A., Hendry B.M. Dual effects of internal n-alkyltrimethylammonium ions on the sodium current of the squid giant axon. J. Physiol. 1985, 361:47-64.
17. England S., de Groot M.J. Subtype-selective targeting of voltage-gated sodium channels. Br. J. Pharmacol. 2009, 158:1413-1425.
18. Haeseler G., Bufler J., Merken S., Dengler R., Aronson J., Leuwer M. Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. Br. J. Pharmacol. 2002, 137:285-293.
19. Haeseler G., Karst M., Foadi N., Gudehus S., Roeder A., Hecker H., Dengler R., Leuwer M. High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br. J. Pharmacol. 2008, 155:265-275.
20. Haeseler G., Mamarvar M., Bufler J., Dengler R., Hecker H., Aronson J.K., Piepenbrock S., Leuwer M. Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol. Br. J. Pharmacol. 2000, 130:1321-1330.
21. Haeseler G., Piepenbrink A., Bufler J., Dengler R., Aronson J.K., Piepenbrock S., Leuwer M. Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. Br. J. Pharmacol. 2001, 132:1916-1924.
22. Hanck D.A., Makielski J.C., Sheets M.F. Lidocaine alters activation gating of cardiac Na channels. Pflugers Arch. 2000, 439:814-821.
23. Hanck D.A., Nikitina E., McNulty M.M., Fozzard H.A., Lipkind G.M., Sheets M.F. Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ. Res. 2009, 105:492-499.
24. Hansch C., Dunn W.J. Linear relationships between lipophilic character and biological activity of drugs. J. Pharm. Sci. 1972, 61:1-19.
25. Haydon D.A., Urban B.W. The action of alcohols and other non-ionic surface active substances on the sodium current of the squid giant axon. J. Physiol. 1983, 341:411-427.
26. Hoyt S.B., London C., Wyvratt M.J., Fisher M.H., Cashen D.E., Felix J.P., Garcia M.L., Li X., Lyons K.A., Euan MacIntyre D., Martin W.J., Priest B.T., Smith M.M., Warren V.A., Williams B.S., Kaczorowski G.J., Parsons W.H. 3-Amino-1,5-benzodiazepinones: potent, state-dependent sodium channel blockers with anti-epileptic activity. Bioorg. Med. Chem. Lett. 2008, 18:1963-1966.
27. Huang C.J., Favre I., Moczydlowski E. Permeation of large tetra-alkylammonium cations through mutant and wild-type voltage-gated sodium channels as revealed by relief of block at high voltage. J. Gen. Physiol. 2000, 115:435-454.
28. Huang C.J., Harootunian A., Maher M.P., Quan C., Raj C.D., McCormack K., Numann R., Negulescu P.A., Gonzalez J.E. Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat. Biotechnol. 2006, 24:439-446.
29. Ilyin V.I., Pomonis J.D., Whiteside G.T., Harrison J.E., Pearson M.S., Mark L., Turchin P.I., Gottshall S., Carter R.B., Nguyen P., Hogenkamp D.J., Olanrewaju S., Benjamin E., Woodward R.M. Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states. J. Pharmacol. Exp. Ther. 2006, 318:1083-1093.
30. Jarvis M.F., Honore P., Shieh C.C., Chapman M., Joshi S., Zhang X.F., Kort M., Carroll W., Marron B., Atkinson R., Thomas J., Liu D., Krambis M., Liu Y., McGaraughty S., Chu K., Roeloffs R., Zhong C., Mikusa J.P., Hernandez G., Gauvin D., Wade C., Zhu C., Pai M., Scanio M., Shi L., Drizin I., Gregg R., Matulenko M., Hakeem A., Gross M., Johnson M., Marsh K., Wagoner P.K., Sullivan J.P., Faltynek C.R., Krafte D.S. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. U S A 2007, 104:8520-8525.
31. Kimbrough J.T., Gingrich K.J. Quaternary ammonium block of mutant Na+ channels lacking inactivation: features of a transition-intermediate mechanism. J. Physiol. 2000, 529(1):93-106.
32. Kondratiev A., Hahin R. ED50 G(Na) block predictions for phenyl substituted and unsubstituted n-alkanols. J. Membr. Biol. 2001, 180:123-136.
33. Kort M.E., Drizin I., Gregg R.J., Scanio M.J., Shi L., Gross M.F., Atkinson R.N., Johnson M.S., Pacofsky G.J., Thomas J.B., Carroll W.A., Krambis M.J., Liu D., Shieh C.C., Zhang X., Hernandez G., Mikusa J.P., Zhong C., Joshi S., Honore P., Roeloffs R., Marsh K.C., Murray B.P., Liu J., Werness S., Faltynek C.R., Krafte D.S., Jarvis M.F., Chapman M.L., Marron B.E. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem. 2008, 51:407-416.
34. Kuo C.C., Bean B.P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol. Pharmacol. 1994, 46:716-725.
35. Li H.L., Galue A., Meadows L., Ragsdale D.S. A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel. Mol. Pharmacol. 1999, 55:134-141.
36. Liang J., Brochu R.M., Cohen C.J., Dick I.E., Felix J.P., Fisher M.H., Garcia M.L., Kaczorowski G.J., Lyons K.A., Meinke P.T., Priest B.T., Schmalhofer W.A., Smith M.M., Tarpley J.W., Williams B.S., Martin W.J., Parsons W.H. Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain. Bioorg. Med. Chem. Lett. 2005, 15:2943-2947.
37. Malawska B., Scatturin A. Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini Rev. Med. Chem. 2003, 3:341-348.
38. McGivern J.G., Patmore L., Sheridan R.D. Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage-dependent sodium currents in the neuroblastoma cell line, N1E-115. Br. J. Pharmacol. 1995, 114:1738-1744.
39. Mike, A., Lukacs, P., The enigmatic drug binding site for sodium channel inhibitors. Curr. Mol. Pharmacol., in press, doi:10.2174/1874210205653834672.
40. Muroi Y., Chanda B. Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J. Gen. Physiol. 2009, 133:1-15.
41. Nau C., Wang S.Y., Strichartz G.R., Wang G.K. Point mutations at N434 in D1-S6 of mu1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. Mol. Pharmacol. 1999, 56:404-413.
42. Nau C., Wang S.Y., Strichartz G.R., Wang G.K. Block of human heart hH1 sodium channels by the enantiomers of bupivacaine. Anesthesiology 2000, 93:1022-1033.
43. O'Leary M.E., Horn R. Internal block of human heart sodium channels by symmetrical tetra-alkylammoniums. J. Gen. Physiol. 1994, 104:507-522.
44. Ogata N., Yoshii M., Narahashi T. Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells. Brain Res. 1989, 476:140-144.
45. Priest B.T., Garcia M.L., Middleton R.E., Brochu R.M., Clark S., Dai G., Dick I.E., Felix J.P., Liu C.J., Reiseter B.S., Schmalhofer W.A., Shao P.P., Tang Y.S., Chou M.Z., Kohler M.G., Smith M.M., Warren V.A., Williams B.S., Cohen C.J., Martin W.J., Meinke P.T., Parsons W.H., Wafford K.A., Kaczorowski G.J. A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model. Biochemistry 2004, 43:9866-9876.
46. Ragsdale D.S., McPhee J.C., Scheuer T., Catterall W.A. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994, 265:1724-1728.
47. Ritchie T.J., Macdonald S.J. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design?. Drug Discov. Today 2009, 14:1011-1020.
48. Rojas E., Rudy B. Destruction of the sodium conductance inactivation by a specific protease in perfused nerve fibres from Loligo. J. Physiol. 1976, 262:501-531.
49. Shao B., Victory S., Ilyin V.I., Goehring R.R., Sun Q., Hogenkamp D., Hodges D.D., Islam K., Sha D., Zhang C., Nguyen P., Robledo S., Sakellaropoulos G., Carter R.B. Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors. J. Med. Chem. 2004, 47:4277-4285.
50. Sheets M.F., Hanck D.A. Molecular action of lidocaine on the voltage sensors of sodium channels. J. Gen. Physiol. 2003, 121:163-175.
51. Sheets P.L., Heers C., Stoehr T., Cummins T.R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 2008, 326:89-99.
52. Spedding M., Kenny B., Chatelain P. New drug binding sites in Ca2+ channels. Trends Pharmacol. Sci. 1995, 16:139-142.
53. Spedding M., Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol. Rev. 1992, 44:363-376.
54. Tarnawa, I., Bolcskei, H., Kocsis, P., 2007. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. Recent Patents on CNS Drug Discovery 2, 57-78.
55. Wang G.K., Simon R., Wang S.Y. Quaternary ammonium compounds as structural probes of single batrachotoxin-activated Na+ channels. J. Gen. Physiol. 1991, 98:1005-1024.
56. Wang Y., Jones P.J., Batts T.W., Landry V., Patel M.K., Brown M.L. Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore. Bioorg. Med. Chem. 2009, 17:7064-7072.
57. Williams B.S., Felix J.P., Priest B.T., Brochu R.M., Dai K., Hoyt S.B., London C., Tang Y.S., Duffy J.L., Parsons W.H., Kaczorowski G.J., Garcia M.L. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry 2007, 46:14693-14703.
58. Xiao Y.F., Wright S.N., Wang G.K., Morgan J.P., Leaf A. Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc. Natl. Acad. Sci. U S A 1998, 95:2680-2685.
59. Yang J., Gharagozloo P., Yao J., Ilyin V.I., Carter R.B., Nguyen P., Robledo S., Woodward R.M., Hogenkamp D.J. 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J. Med. Chem. 2004, 47:1547-1552.
60. Zuliani V., Patel M.K., Fantini M., Rivara M. Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. Curr. Top. Med. Chem. 2009, 9:396-415.